Publication

Video

Supplements and Featured Publications

Year in Review: Updates in DLBCL Treatment
Volume1
Issue 1

Dr. Pagel on the Evolution of Treatment in DLBCL

John M. Pagel, MD, PhD, discusses the evolution of treatment in diffuse large B-cell lymphoma.

John M. Pagel, MD, PhD, chief of the Hematologic Malignancies Program, and director, Hematopoietic Cell Transplantation Program, at Swedish Cancer Institute, discusses the evolution of treatment in diffuse large B-cell lymphoma (DLBCL).

Currently, at least 60% of patients with DLBCL are cured with available therapeutic options, Pagel says.

However, treatment should be tailored based on the patient’s specific subtype of DLBCL as not all large cell lymphomas require the same course of treatment, explains Pagel. Moreover, it is necessary to understand whether the cell of origin is a germinal center or non-germinal center as this can influence treatment selection and prognosis.

In the frontline setting, the addition of rituximab (Rituxan) to standard CHOP-based chemotherapy served as a pivotal advance in the space, Pagel says.

Additionally, other recent advances have reformed the treatment paradigm for patients with relapsed/refractory DLBCL, concludes Pagel.

Related Videos
Alberto Montero, MD, MBA, CPHQ, clinical director, Breast Cancer Medical Oncology Program, University Hospitals Seidman Cancer Center; associate professor, medicine, Case Western Reserve University School of Medicine
JURCZACK
Adam E. Singer, MD, PhD, health sciences clinical instructor, medicine, division lead, Kidney Cancer, Division of Hematology/Oncology, UCLA Health
Dr Burke on the Assessment of Barriers to Initiating Venetoclax-Based Regimens for CLL
Bradley McGregor, MD,
Ira Zackon, MD
Jacob E. Berchuck, MD
David A. Braun, MD, PhD
Christiane Querfeld, M.D., Ph.D
Judy Hayek, MD